Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1

Leukemia

Volumn 25, Issue 5, 2011, Pages 838-847

  Huber, S ^a   Oelsner, M ^a   Decker, T ^a,b   Zum Büschenfelde, C Meyer ^a   Wagner, M ^a   Lutzny, G ^a   Kuhnt, T ^a   Schmidt, B ^c   Oostendorp, R A J ^a   Peschel, C ^a   Ringshausen, I ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Onkologie Ravensburg   (Germany)

^c Hamatol/Internistische Onkologie   (Germany)

Author keywords

CLL; Mcl 1; sorafenib

Indexed keywords

BEVACIZUMAB; CASPASE 3; CASPASE 9; CD38 ANTIGEN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; PROTEIN MCL 1; SMALL INTERFERING RNA; SORAFENIB;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STROMA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, SMALL INTERFERING; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 79955809893     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.2     Document Type: Article

References (40)

1. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951. (Pubitemid 36857758)
2. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
3. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresis-tance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95: 513-517. (Pubitemid 26388693)
4. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclopho-sphamide, and rituximab. Blood 2009; 113: 535-537.
5. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008; 112: 3807-3817.
6. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181-3187.
7. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001; 7: 795-799. (Pubitemid 32708712)
8. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16: 911-919. (Pubitemid 34537565)
9. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004; 28: 243-248. (Pubitemid 37550058)
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. (Pubitemid 46089673)
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
12. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
13. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
14. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280: 35217-35227. (Pubitemid 41532709)
15. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088. (Pubitemid 46211313)
16. Kusadasi N, Oostendorp RA, Koevoet WJ, Dzierzak EA, Ploemacher RE. Stromal cells from murine embryonic aorta-gonad-mesonephros region, liver and gut mesentery expand human umbilical cord blood-derived CAFC(week6) in extended long-term cultures. Leukemia 2002; 16: 1782-1790.
17. Oostendorp RA, Harvey KN, Kusadasi N, de Bruijn MF, Saris C, Ploemacher RE et al. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood 2002; 99: 1183-1189. (Pubitemid 34547069)
18. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972. (Pubitemid 46202316)
19. Zum Büschenfelde CM, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, Decker T et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010; 24: 141-152.
20. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
21. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867. (Pubitemid 38410730)
22. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 2002; 99: 2969-2976. (Pubitemid 34525387)
23. Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008; 22: 1226-1233. (Pubitemid 351833791)
24. Majolini MB, D'Elios MM, Galieni P, Boncristiano M, Lauria F, Del Prete G et al. Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood 1998; 91: 3390-3396. (Pubitemid 28193891)
25. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23: 7863-7873. (Pubitemid 39457036)
26. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497-4503.
27. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
28. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006. (Pubitemid 30062724)
29. Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002; 16: 327-334. (Pubitemid 34228819)
30. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 2006; 5: 2378-2387. (Pubitemid 44530475)
31. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609-4614. (Pubitemid 35429705)
32. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007; 109: 2032-2039. (Pubitemid 46348203)
33. Veronese L, Tournilhac O, Verrelle P, Davi F, Dighiero G, Chautard E et al. Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. Leuk Res 2009; 33: 1623-1626.
34. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005; 19: 524-530. (Pubitemid 40521154)
35. Paesler J, Gehrke I, Gandhirajan RK, Filipovich A, Hertweck M, Erdfelder F et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res 2010; 16: 3390-3398.
36. Ho CL, Hsu LF, Phyliky RL, Li CY. Autocrine expression of platelet-derived growth factor B in B cell chronic lymphocytic leukemia. Acta Haematol 2005; 114: 133-140. (Pubitemid 41540335)
37. Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC et al. Platelet derived growth factor (PDGF)FPDGF receptor interaction activates bone marrow derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010; 116: 2984-2993.
38. Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994; 24: 445-451. (Pubitemid 24192314)
39. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764. (Pubitemid 40322252)
40. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472-5480. (Pubitemid 41060823)